Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07593625Recruiting
Testing a new insulin pump algorithm for type 1 diabetes
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
ChristchurchAges 2–70 - NCT07712809Enrolling by invitation
Testing a connected care platform for kids with type 1 diabetes
This study tests a new online platform that connects your child's diabetes devices (glucose monitor and insulin pump) with their healthcare team. The goal is to help doctors and nurses see your child's data in real time and provide better care.
Vancouver, British ColumbiaAges 3–18 - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Boston, MassachusettsAges 18 years+ - NCT06136728RecruitingPhase 3
Dalfampridine and physical therapy for walking problems in MS
This trial tests whether adding dalfampridine to physical therapy helps people with multiple sclerosis walk better. You must not already be taking dalfampridine or getting physical therapy to join.
Boston, MassachusettsAges 25–75 - NCT06810739Recruiting
Women's Screening and Self-Testing Program (PROMETA)
This study tests a self-screening program for cervical cancer among women who are already receiving HIV care. It aims to make screening easier and more accessible.
MaputoAges 25–49 - NCT06143514Recruiting
Study of BRIUMVI in breast milk
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
San Francisco, CaliforniaAges 18 years+ - NCT06361537RecruitingPhase 3
Study of a C1 inhibitor medicine for HAE attacks
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
Centennial, ColoradoAges 2 years+ - NCT07409428RecruitingPhase 3
Study of HMPL-760 plus R-GemOx for relapsed or refractory DLBCL
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05849753Recruiting
Access program for diabetes tech in kids with type 1
This trial helps children with type 1 diabetes get advanced diabetes technology, aiming to reduce gaps in access for families with fewer resources. It will check whether these tools are usable and helpful for diabetes care in children who meet the study needs.
Jacksonville, FloridaAges 6–17 - NCT07149142Recruiting
AI eye screening for children with type 1 diabetes
This study tests if an artificial intelligence (AI) system can effectively screen for eye problems related to diabetes (retinopathy) in children. The goal is to find a faster, easier way to protect your child's vision.
Prague, Prague 5Ages 11–19 - NCT05188014Recruiting
Exercise timing your menstrual cycle in type 1 diabetes
This study looks at how doing exercise at different points in your menstrual cycle affects blood sugar control in people with type 1 diabetes. It may help you and your care team understand how to plan exercise more safely and effectively around your period.
Edmonton, AlbertaAges 18–50 - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Ramat GanAges 1–30 - NCT05729256Recruiting
Study on alcohol and impulsive sexual choices in gay men
This study looks at how heavy drinking may affect “heat of the moment” sexual decisions and related thinking. You may be able to take part if you meet specific recent sex and drinking criteria.
Boston, MassachusettsAges 18 years+ - NCT07710105Recruiting
Ocrevus for MS: A Real-World Study
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
Chicago, IllinoisAges 18 years+ - NCT06932263RecruitingPhase 2
Testing tozorakimab for uncontrolled asthma
This trial tests a new drug called tozorakimab for adults whose asthma is not well controlled despite using medium-to-high dose inhaled steroids. The study aims to find the best dose and see if it reduces asthma attacks.
Bakersfield, CaliforniaAges 18–75 - NCT07060274Recruiting
How fast does the halo sign vanish after steroids in GCA?
This trial is for people newly diagnosed with giant cell arteritis (GCA) who have a 'halo' sign on their temporal artery ultrasound. It will study how quickly the halo disappears after starting steroid treatment, helping doctors understand the best way to use steroids for this condition.
Le Mans, SartheAges 50 years+ - NCT06688331RecruitingPhase 2
Treating early stage 1 type 1 diabetes in children with cell therapy and antibody
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
BialystokAges 3–18 - NCT07710248RecruitingPhase 2
Safety of SG301-SC in adults with ITP
This study tests a new injection called SG301-SC for people with primary immune thrombocytopenia (ITP) whose platelet counts stay low even after standard treatments. The goal is to see if it is safe and helps raise platelets, reducing bleeding risk.
Fuzhou, FujianAges 18–75 - NCT05052528RecruitingPhase 1
CAR T cell therapy for relapsed or refractory large B-cell lymphoma
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
Sacramento, CaliforniaAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT07039422RecruitingPhase 2
Ianalumab re-treatment for ITP or wAIHA
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Buenos AiresAges 18–100 - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT04692493RecruitingPhase 3
Testing two treatment paths for active rheumatoid arthritis
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Auburn, AlabamaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.